Cannabix Technologies Provides Update on THC Breathalyzer Beta-Testing

Vancouver, British Columbia, June 1, 2021 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it expects to ship its THC Breath Analyzer (“THCBA”) to a clinic in the Northwestern U.S. for beta testing in the coming days. The collaborating clinic has a robust drug testing operation and is one of the top drug testing providers to employers within its respective state. This new beta-testing site will be an addition to beta-testing launched earlier in the year. The Company is also reviewing new opportunities for testing in the province of Ontario.

The Company has received early positive qualitative feedback of its THCBA device with regards to human factors usage of the device. Beta-testing has been ongoing with Alipour Medical Centre, an occupational health care provider located in Newport Beach California.  

Dr. Nima Alipour, Chief Medical Officer of AMC, the Occupational Medicine Division of Hybrid Health Systems, stated, “My team and I have found the THCBA easy to use and have been impressed with its intuitive administrative and user functionality with the capacity to complete a breath test within 5 minutes per subject, we think this will be important for employers who conduct drug testing in various work environments and require quick results.  We have provided feedback on breath sample collection, connectivity, battery management, handling and sanitation of the device.  As occupational health practitioners based in California, we understand the challenges that employers are facing in providing relevant drug testing for both new and existing employees.  This is an exciting new tool that can move drug testing for cannabis forward from where it is now, to providing actionable insights on impairment vs. legal and prescribed use.”

Cannabix is seeking and reviewing additional beta-testing sites. Beta-testing of the THCBA prototype is focused on improving user and administrator experience, identifying cross-reactivity of other substances within a semi-controlled study population and to further train the device’s machine learning database and sensitivity profile. The THCBA is a drug screening device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.

The Company also reports that it has expanded its facility in Burnaby, BC to among other things, accommodate assembly of more devices and bring on additional staff.